• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by SELLAS Life Sciences Group Inc.

    8/12/25 4:38:00 PM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SLS alert in real time by email
    S-8 1 tm2523289d1_s8.htm FORM S-8

    As filed with the Securities and Exchange Commission on August 12, 2025

     

    Registration No. 333-

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

    _______________

     

    FORM S-8

    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933

    _______________

     

    SELLAS Life Sciences Group, Inc.

    (Exact name of registrant as specified in its charter)

    _______________

     

    Delaware

    20-8099512

    (State or other jurisdiction
    of incorporation or organization)
    (I.R.S. Employer
    Identification No.)

     

    7 Times Square, Suite 2503
      New York, NY 10036

     

    (Address of Principal Executive Offices) (Zip Code)

    _______________

     

    SELLAS Life Sciences Group, Inc. Amended and Restated 2021 Employee Stock Purchase Plan

    (Full title of the plan)

    _______________

     

    Angelos M. Stergiou, M.D., ScD h.c.

    President and Chief Executive Officer

    SELLAS Life Sciences Group, Inc.

    7 Times Square, Suite 2503

    New York, NY 10036

    Telephone: (640) 200-5278

    (Name and address of agent for service)

    (Telephone number, including area code, of agent for service)

     

    Copies to:

     

    Joel I. Papernik, Esq.

    Daniel A. Bagliebter, Esq.

    Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

    919 Third Avenue, New York, NY 10022

    (212) 935-3000

    _______________

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
        Emerging growth company ☐

     

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

    EXPLANATORY NOTE

     

    SELLAS Life Sciences Group, Inc. (the “Registrant”) has prepared this Registration Statement on Form S-8 (the “Registration Statement”) in accordance with the requirements of Form S-8 under the Securities Act of 1933, as amended (the “Securities Act”), to register 800,000 additional shares of common stock, par value $0.0001 per share (“Common Stock”), for issuance under the SELLAS Life Sciences Group, Inc. Amended and Restated 2021 Employee Stock Purchase Plan (the “Plan”), representing an increase of 800,000 shares reserved under the Plan, as approved by the Registrant’s stockholders at the Registrant’s annual meeting of stockholders on June 17, 2025.

     

    This Registration Statement registers additional securities of the same class as other securities for which the registration statement filed on Form S-8 (SEC File Nos. 333-237168, 333-258799, 333-264899, 333-270608, and 333-276615) of the Registrant is effective. The information contained in the Registrant’s registration statements on Form S-8 filed with the Securities and Exchange Commission on March 13, 2020 (File No. 333-237168), August 13, 2021 (File No. 333-258799), May 12, 2022 (File No. 333-264899), March 16, 2023 (File No. 333-270608), and January 19, 2024 (333-276615) is hereby incorporated by reference pursuant to General Instruction E of Form S-8.

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 8. Exhibits.

     

    Exhibit
    Number
      Exhibit Description   Filed
    Herewith
      Incorporated by
    Reference herein from
    Form or Schedule
      Filing Date   SEC File/
    Reg.
    Number
                         
    3.1   Composite Amended and Restated Certificate of Incorporation of the Registrant (formerly, Galena Biopharma, Inc.), amended as of December 27, 2017       Form 10-K
    (Exhibit 3.1)
      April 13, 2018   001-33958
                         
    3.2   Certificate of Amendment to the Amended and Restated Certificate of Incorporation       Form 10-K
    (Exhibit 3.3)
      March 23, 2021   001-33958
                         
    3.3   Amended and Restated By-Laws of the Registrant       Form 8-K
    (Exhibit 3.3)
      January 5, 2018   001-33958
                         
    5.1   Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.   X            
                         
    23.1   Consent of Baker Tilly US, LLP, independent registered public accounting firm.   X            
                         
    23.2   Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in Exhibit 5.1)   X            
                         
    24.1   Power of Attorney (included on the signature page hereof)   X            
                         
    99.1+   SELLAS Life Sciences Group, Inc. Amended and Restated 2021 Employee Stock Purchase Plan       Form 10-Q
    (Exhibit 10.1)
      August 12, 2025   001-33958
                         
    107   Filing Fee Table   X            

     

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, New York, on August 12, 2025.

     

      SELLAS LIFE SCIENCES GROUP, INC.
       
      By: /s/ Angelos M. Stergiou     
      Angelos M. Stergiou, M.D., ScD h.c.
      President and Chief Executive Officer

     

    Each person whose signature appears below constitutes and appoints each of Angelos M. Stergiou and John T. Burns, acting alone or together with another attorney-in-fact, as his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for such person and in his or her name, place and stead, in any and all capacities, to sign any or all further amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof. Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the date indicated.

     

    Signature

    Title

    Date

    /s/ Angelos M. Stergiou

    President, Chief Executive Officer and Director (Principal Executive Officer) August 12, 2025
    Angelos M. Stergiou, M.D., ScD h.c.
         

    /s/ John T. Burns

    Senior Vice President, Chief Financial Officer (Principal Financial and Accounting Officer) August 12, 2025
    John T. Burns    
         

    /s/ John Varian

    Chair of the Board of Directors August 12, 2025
    John Varian    
         

    /s/ David Scheinberg

    Director August 12, 2025
    David Scheinberg, M.D., PhD.    
         

    /s/ Robert Van Nostrand

    Director August 12, 2025
    Robert Van Nostrand    
         

    /s/ Jane Wasman

    Director August 12, 2025
    Jane Wasman    
         
         

    /s/ Katherine Kalin

    Director August 12, 2025
    Katherine Kalin    

     

     

     

     

    Get the next $SLS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SLS

    DatePrice TargetRatingAnalyst
    7/21/2021$18.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $SLS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Van Nostrand Robert L bought $14,800 worth of shares (10,000 units at $1.48), increasing direct ownership by 96% to 20,400 units (SEC Form 4)

    4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)

    6/13/25 8:00:33 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Wasman Jane bought $33,800 worth of shares (20,000 units at $1.69), increasing direct ownership by 192% to 30,400 units (SEC Form 4)

    4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)

    6/2/25 4:42:07 PM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Kalin Katherine Bach bought $36,000 worth of shares (20,000 units at $1.80), increasing direct ownership by 95% to 41,000 units (SEC Form 4)

    4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)

    5/22/25 4:05:17 PM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Van Nostrand Robert L bought $14,800 worth of shares (10,000 units at $1.48), increasing direct ownership by 96% to 20,400 units (SEC Form 4)

    4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)

    6/13/25 8:00:33 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Wasman Jane bought $33,800 worth of shares (20,000 units at $1.69), increasing direct ownership by 192% to 30,400 units (SEC Form 4)

    4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)

    6/2/25 4:42:07 PM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Kalin Katherine Bach bought $36,000 worth of shares (20,000 units at $1.80), increasing direct ownership by 95% to 41,000 units (SEC Form 4)

    4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)

    5/22/25 4:05:17 PM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SELLAS Life Sciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    - Positive IDMC Recommendation to Continue Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in AML Without Modification; Final Analysis Anticipated by Year-end 2025 –- Reported Positive Phase 2 Results of SLS009 in Relapsed/Refractory (r/r) Acute Myeloid Leukemia (AML) with Trial Meeting All Primary Endpoints; Full Data Presentation Expected Later This Year -- Alignment with FDA to Advance SLS009 in a First-Line AML Trial with Enrollment Anticipated by Q1 2026 -- $25.3 million in Cash and Cash Equivalents as of June 30, 2025; Additional $4.0 million Proceeds Received in July 2025 for Warrant Exercises - NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NAS

    8/12/25 4:05:00 PM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification

    -        Final Analysis Anticipated by Year-End Upon Occurrence of 80 Events        - NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the Independent Data Monitoring Committee (IDMC) has completed a pre-specified analysis of the Phase 3 REGAL trial of galinpepimut-S (GPS) in acute myeloid leukemia (AML), and has issued a positive recommendation to continue the trial without modification. The IDMC concluded that the risk-benefit profile of GPS supports cont

    8/7/25 8:30:00 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SELLAS Meets All Primary Endpoints in Phase 2 Trial of SLS009 in r/r AML and Receives FDA Guidance to Advance into First-Line Therapy Study

    The Trial Exceeded Target Overall Response Rate (ORR) of 20%, with 44% Response Rate Among Patients with Acute Myeloid Leukemia-Myelodysplasia-Related Changes (AML MR) Treated at Optimal Dose of 30 mg Twice a Week (BIW) and 50% in AML MR with Myelomonocytic/Myelomonoblastic (M4/M5) SubtypeMedian Overall Survival (mOS) of 8.9 Months in Patients with AML MR and 8.8 mOS in Relapsed or Refractory to Venetoclax-Based Regimens at 30 mg BIW Dose Level Surpasses the Historical Benchmark of 2.4 MonthsFDA Recommends Advancement towards a Trial Including Newly Diagnosed First-Line AML Patient Cohorts That May Support a New Drug Application; Trial Preparation Underway with Enrollment Expected to Begin b

    7/15/25 7:45:00 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLS
    SEC Filings

    View All

    SEC Form S-8 filed by SELLAS Life Sciences Group Inc.

    S-8 - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)

    8/12/25 4:38:00 PM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SELLAS Life Sciences Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)

    8/12/25 4:07:59 PM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by SELLAS Life Sciences Group Inc.

    10-Q - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)

    8/12/25 4:00:58 PM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on SELLAS Life Sciences with a new price target

    Cantor Fitzgerald initiated coverage of SELLAS Life Sciences with a rating of Overweight and set a new price target of $18.00

    7/21/21 11:28:03 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RBC Capital initiated coverage on Solaris Resources with a new price target

    RBC Capital initiated coverage of Solaris Resources with a rating of Outperform and set a new price target of $18.00

    6/21/21 6:52:33 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLS
    Leadership Updates

    Live Leadership Updates

    View All

    SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board

    NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the addition of Linghua Wang, MD, PhD, to its Scientific Advisory Board (SAB). Dr. Wang is a widely respected leader in cancer research and translational science, and she joins the Company's SAB shortly after the appointments of Philip C. Amrein, MD, and Dr. Alex Kentsis, MD, PhD. "We are thrilled to welcome Dr. Wang to our Scientific Advisory Board," said Dragan Cicic, MD, Senior Vice President, Chief Development Officer

    7/7/25 8:45:00 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices

    Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- Equity Insider News Commentary – Rising rates of cancer are going to come at a major cost, and it's looking more and more like the solution is going to have to come from the private sector. Recent reports suggest the U.S. government may slash National Cancer Institute (NCI) funding by nearly 40%, while Bloomberg reports growing concern over affordability and access to cancer drugs whose prices are rising sharply. From Wall Street's point of view, the focus needs to shift towards up-and-coming treatments being developed by promising candidates, including from Oncolytics Biot

    6/24/25 12:52:00 PM ET
    $AUTL
    $CATX
    $INDP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical/Dental Instruments
    Biotechnology: Pharmaceutical Preparations

    SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts

    NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the appointment of two distinguished oncology leaders to its Scientific Advisory Board (SAB). The new members – Philip C. Amrein, MD, and Alex Kentsis, MD, PhD bring decades of expertise in cancer research, clinical oncology, and translational medicine, further strengthening the company's strategic guidance as it advances its therapeutic pipeline. "We are honored to welcome Drs. Amrein and Kentsis to our Scientific Advisor

    6/5/25 8:45:00 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLS
    Financials

    Live finance-specific insights

    View All

    SELLAS Life Sciences to Host Virtual Investor Symposium on its Lead Asset, Galinpepimut-S, on September 15, 2022

    NEW YORK, Sept. 08, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today reminds the investment community that it will host a virtual investor symposium on its lead asset, galinpepimut-S (GPS), including the potential commercial opportunity for GPS in AML patients. The conference call and webcast will be held on Thursday, September 15, 2022, from 1:00 p.m. to 2:00 p.m. ET featuring remarks from Angelos Stergiou, M.D., Sc.D. h.c., President and Chief Executive Officer, and Robert Francomano, Chief Commer

    9/8/22 8:00:00 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SELLAS Life Sciences Reports Third Quarter 2021 Financial Results and Provides Business Update

    NEW YORK, Nov. 12, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today reported its financial results for the quarter ended September 30, 2021 and provided a business update. "During the third quarter of 2021, in addition to continuing to enroll patients in the United States and Europe for our Phase 3 REGAL study of galinpepimut-S (GPS) in acute myeloid leukemia (AML) patients, we also commenced clinical and regulatory preparations for a potential new Phase 2/3 study of GPS in AML patients following a bon

    11/12/21 8:45:00 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SELLAS Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Update

    Reported Promising Updated Clinical Data in Ongoing Clinical Trials of Galinpepimut-S (GPS) in Combination with PD-1 Inhibitors for Malignant Pleural Mesothelioma (MPM) and WT1+ Advanced Ovarian Cancer Recently Published Outcomes Data for Acute Myeloid Leukemia (AML) Patients Highlights Continued Unmet Need and Expanded Market Opportunity for GPS Cash Position of $29.9 million as of June 30, 2021 To Host Virtual Investor Symposium on GPS on August 17, 2021 NEW YORK, Aug. 12, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad ran

    8/12/21 4:22:52 PM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by SELLAS Life Sciences Group Inc.

    SC 13G/A - SELLAS Life Sciences Group, Inc. (0001390478) (Subject)

    11/8/24 8:33:00 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by SELLAS Life Sciences Group Inc.

    SC 13G - SELLAS Life Sciences Group, Inc. (0001390478) (Subject)

    2/7/24 3:01:47 PM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - SELLAS Life Sciences Group, Inc. (0001390478) (Subject)

    2/16/21 10:08:07 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care